Table 3.

Unadjusted and Adjusted Days Until First Protease Inhibitor Use by Patient-Provider Race Groups (95% Confidence Intervals)

	White Providers		African-American Providers
	White Patients	African-American Patients	White Patients	African-American Patients
Stage 1: unadjusted	278 (258 to 304)	443 (392 to 503)‡	206 (99 to 458)	419 (337 to 551)†
Stage 2: adjusted for patient characteristics	353 (317 to 386)	461 (404 to 520)†	251 (160 to 422)	342 (269 to 429)
Stage 3: adjusted for patient and provider characteristics	377 (335 to 413)	460 (393 to 516)*	227 (125 to 375)	285 (219 to 369)*
Stage 4: adjusted for patient, provider and attitude characteristics	383 (340 to 419)	467 (397 to 522)*	223 (122 to 351)*	288 (222 to 368)*

^*P < .05 for comparison to white patients with white providers.

^†P < .01 for comparison to white patients with white providers.

^‡P < .001 for comparison to white patients with white providers.

Patient covariates are age, gender, education, annual family income, type of health insurance, self-reported access to care, primary HIV risk factor, recent heavy alcohol or drug use, CD4 count, symptom burden index, and geographic region. Provider covariates are gender, sexual orientation, years in practice, specialty/expertise, HIV knowledge, practice setting, belief that patients cannot adhere to antiretrovirals, preference not to treat injection drug users, and belief that antiretroviral therapy should be withheld or delayed for nonadherent patients. Attitude covariates are trust in provider, rating of medical care, and belief that antiretrovirals are worth taking.